|drug3946||mouthrinse without bêta-cyclodextrin and citrox Wiki||1.00|
|drug3945||mouthrinse with bêta-cyclodextrin and citrox Wiki||1.00|
There is one clinical trial.
NLR has previously been observed to correlate with complications in upper GI (1) and colorectal (2) surgery. The investigators sought to assess if a similar correlation can be identified in emergency general surgical patients and if the presence of suspected or confirmed COVID-19 may impact on this. Given the heterogeneity of emergency general surgery the investigators therefore plan to perform a retrospective review of patients having emergency laparotomies only at a single NHS site during COVID-19 pandemic. Assessment of outcomes and Neutrophil:lymphocyte ratio as a predictor of outcomes will be completed. Outcomes will be completed in line with the recent COVIDSurg study criteria (3). The primary outcome is 30-day mortality. Secondary outcomes are 7-day mortality, re-operation, length of stay, post-operative respiratory failure, post-operative ARDS (Acute Respiratory Distress Syndrome), post-operative sepsis and ITU (Intensive Therapy Unit)/HDU (High Dependency Unit) admission.
Description: MortalityMeasure: 30-day mortality Time: 30 days
Description: MortalityMeasure: 7-day mortality Time: 7 days
Description: Re-operationMeasure: Number of participants returning to theatre Time: 30 days
Description: Inpatient stay during index admissionMeasure: Length of stay Time: 30 days
Description: Presence of respiratory failure in the post-operative period as defined in the clinical notes or discharge summariesMeasure: Post-operative respiratory failure Time: 30 days
Description: ARDS diagnosed radiologicallyMeasure: Post-operative ARDS Time: 30 days
Description: Presence of sepsis in the post-operative period as defined in the clinical notes or discharge summariesMeasure: Post-operative sepsis Time: 30 days
Description: ITU/HDU admission post-operativelyMeasure: ITU/HDU admission Time: 30 days
Description: Other documented post-operative complicationsMeasure: Other complications Time: 30 days
Description: Neutrophil:Lymphocyte Ratio will be recorded daily in the peri-operative periodMeasure: Peri-operative NLR Time: First 3 post-operative days
Description: Absolute platelet counts recorded daily in the peri-operative periodMeasure: Post-operative platelet counts Time: First 3 post-operative days
Description: Defined as the presence of increased PT (prothrombin time) OR APTT (activated partial thromboplastin time) OR TT (thrombin time) OR fibrinogen above 1.5X the upper limit of normal. Coagulation will either be defined as normal or abnormal for each patient if one or more of these derangement are identified.Measure: Post-operative coagulopathy Time: First 3 post-operative days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports